# OrphanCure Full Pipeline Report: repodb_074e03e7fac6728e

- Drug: Irinotecan
- Disease: signet ring adenocarcinoma of the rectum
- Mode: no_verifier
- Status: completed
- Final assessment: Unlikely

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Unlikely",
      "confidence": "Low",
      "summary": "No literature was retrieved to support or refute the repurposing of Irinotecan for rectal signet ring cell adenocarcinoma. Therefore, based on the current data, this repurposing is unlikely.",
      "evidence_counts": {
        "total_papers": 0,
        "supporting": 0,
        "contradicting": 0,
        "inconclusive": 0
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose IRINOTECAN for rectal signet ring cell adenocarcinoma",
      "drug": {
        "id": "CHEMBL481",
        "name": "IRINOTECAN",
        "aliases": [
          "CPT-11",
          "Camptosar",
          "Irinotecan hydrochloride",
          "Onivyde",
          "Topoisomerase 1 inhibitor"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "MONDO_0004336",
        "name": "rectal signet ring cell adenocarcinoma",
        "aliases": [
          "Signet ring cell adenocarcinoma of rectum",
          "Rectal SRC adenocarcinoma",
          "Adenocarcinoma, signet ring cell, of rectum",
          "Rectal signet ring carcinoma",
          "Signet ring cell carcinoma of the rectum"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 0,
      "polarity": {
        "supports": 0,
        "contradicts": 0,
        "inconclusive": 0
      },
      "support_ratio": "No papers retrieved",
      "queries_used": 10,
      "top_papers": []
    },
    "6_contradictory_evidence": {
      "count": 0,
      "claims": []
    },
    "7_confidence_assessment": {
      "overall": "Low",
      "dimensions": {
        "mechanistic_strength": "Low",
        "literature_strength": "Low",
        "clinical_evidence": "Low"
      },
      "quality_scorecard": {
        "overall_score": 0.388,
        "decision": "rerun",
        "dimensions": {
          "completeness": {
            "score": 0.8,
            "reason": "4/5 sections present"
          },
          "evidence_support": {
            "score": 0.0,
            "reason": "No claims generated"
          },
          "citation_validity": {
            "score": 0.0,
            "reason": "0 total citations"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/0 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.3,
            "reason": "No contradiction analysis"
          },
          "traceability": {
            "score": 0.0,
            "reason": "0/0 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "evidence_support",
          "citation_validity",
          "mechanistic_specificity",
          "contradiction_handling",
          "traceability"
        ],
        "rerun_targets": [
          "LiteratureAgent",
          "MechanismAgent",
          "SynthesisCriticAgent"
        ]
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Lack of specific evidence for this rare subtype and location."
      ],
      "limitations": [
        "The absence of retrieved literature indicates a significant data gap.",
        "The conclusion is based solely on the lack of evidence, not on any positive or negative findings."
      ],
      "missing_data": [
        "Preclinical data on Irinotecan's efficacy against rectal signet ring cell adenocarcinoma.",
        "Clinical trial data for Irinotecan in this specific indication.",
        "Mechanistic studies linking Irinotecan's targets to the biology of rectal signet ring cell adenocarcinoma."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Conduct a thorough literature search for any preclinical or clinical studies investigating Irinotecan in signet ring cell adenocarcinoma, specifically in the rectal location.",
        "If no direct evidence is found, explore studies on Irinotecan's efficacy in other signet ring cell adenocarcinomas (e.g., gastric) to infer potential relevance.",
        "Consider in vitro or in vivo studies to assess Irinotecan's activity against rectal signet ring cell adenocarcinoma cell lines or models."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 0,
      "claims": []
    },
    "11_provenance_appendix": {
      "total_entries": 0,
      "entries": []
    }
  },
  "metadata": {
    "run_id": "97553ae64fa1",
    "created_at": "2026-06-03T14:38:31.149805+00:00",
    "drug": "IRINOTECAN",
    "disease": "rectal signet ring cell adenocarcinoma",
    "total_claims": 0,
    "quality_score": 0.3875,
    "reruns": 0
  }
}
```
